Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting
AIRPORT CITY, Israel, April 28, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced an abstract has been accepted for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held virtually from June 4-8, 2021.
Title: Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.
Presenter: Jessica K. Altman, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Session Date and Time: June 4, 2021, 2:30 PM-5:30 PM EDT
About Aspacytarabine (BST-236)
Aspacytarabine was granted FDA Fast Track Designation for treatment of AML patients unfit for standard chemotherapy, and FDA and EMA Orphan Drug Designations, which entitle Biosight to seven and ten years of market exclusivity in the U.S. and Europe, respectively, upon aspacytarabine marketing approval for the treatment of AML in each territory.
Interim results from an ongoing Phase 2b study evaluating aspacytarabine as a single-agent first-line AML therapy demonstrate safety and single-agent activity, and additional studies are launched to evaluate aspacytarabine as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or AML. For more information regarding the Phase 2b clinical study of BST-236, please visit www.clinicaltrials.gov.
About Biosight Ltd.
Fireside Chat -- AIOps, Analytics
Networking LIVE! Reception - On the Amazing Spacious Seaside Patio of the Loews Miami Beach Resort